Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × NSCLC × famitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Solid Tumor 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Melanoma 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gefitinib 5 icotinib 4 Pemetrexed 4 Docetaxel 4 camrelizumab 3 apatinib 3 anlotinib 3 aflutinib 3 Erlotinib Hydrochloride 3 osimertinib 2 dacomitinib 2 Thalidomide 2 Radiosurgery 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 trilaciclib 1 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 famitinib 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiofrequency Ablation 1 Microphysiological Systems 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05005468 2021-08-13

CAMFA-L

Shanghai Chest Hospital

Phase 2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡